NéevoDHA®

NéevoDHA® is a multivitamin/multi-mineral nutritional supplement for women who require increased vitamin, mineral and essential fatty acid concentrations throughout pregnancy and the post natal period for both lactating and non-lactating mothers. It can be used prior to conception to improve nutrition.

NéevoDHA® has become one of the nation's fastest growing and largest prescription prenatal vitamins

NéevoDHA® includes 1mg of L-methylfolate (Metafolin®). L-methylfolate is the biologically, active form of folate that the body needs during pregnancy. L-methylfolate doesn't have the MTHFR polymorphism limitations that folic acid does.1 Moreover, L-methylfolate is 7x more bioavailable than synthetic folic acid.2

NéevoDHA® includes 1mg of Methylcobalamin. Methylcobalamin is the active metabolized form of B12. Most prenatal vitamins only supply 12mcg of B12. NéevoDHA® supplies a significantly higher amount to aid in the production of red blood cells and to help metabolize homocysteine into methionine (along with folate in the cellular methylation cycle).

NéevoDHA® is certified kosher. Triangle K & Associates of NYC has certified our product to be kosher in meeting the high standards of manufacturing quality as well as dietary regulations. We are proud to have earned this certification.

  1. Molloy A, et al Thermolabile variant of 5, 10-methlenetetrahydrofolate reductase associated with low red-cell folates: implications for folate intake recommendations Lancet 1997; 349: 1591-93.
  2. Willems FF, Boers GH, Blom HJ, et al. Pharmacokinetic Study on the Utilization of 5-methyltetrahydrofolate and Folic Acid in Patients with Coronary Artery Disease. Br J Pharmacol 2004; 141:825-830.
More from our Product Family
  • Metanx®: The active, natural occurring B-vitamins in Metanx® are directly associated with metabolizing homocysteine, a risk factor for vascular disease, and improving the overall health of the blood vessels.
  • Deplin®Zn is a medical food indicated for the distinct nutritional requirements of patients under a physician's treatment for hyperhomocysteinemia with particular emphasis for those individuals diagnosed with chronic kidney disease (CKD), end stage renal disease (ESRD) or dialysis.